Understanding Joint Inflammation Linked to Cancer Immunotherapy

Understanding Joint Inflammation Linked to Cancer Immunotherapy-715x405

Cancer immunotherapy has transformed treatment for several types of cancer by helping the immune system recognize and attack cancer cells. However, these treatments can also cause the immune system to attack healthy tissues.

One possible side effect is inflammatory arthritis, which causes joint pain, swelling and stiffness. A review article by Arthritis Research Canada scientist Dr. Carrie Ye and clinician investigator Dr. Shahin Jamal, published in Nature Reviews Rheumatology, examines what is known about this condition, called immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA), and the challenges it presents for patients and health-care providers.

ICI-IA is the most common rheumatic immune-related side effect of immune checkpoint inhibitor treatment. Unlike many other side effects of immunotherapy, it can persist long after treatment ends.

“Cancer immunotherapy works by helping the immune system fight cancer. But the same immune processes can also contribute to inflammation in the joints,” says Dr. Ye. “Recognizing this side effect is important because joint symptoms can continue even after cancer treatment has stopped.”

A distinct form of inflammatory arthritis

ICI-IA has features that distinguish it from rheumatoid arthritis and other forms of inflammatory arthritis. It can affect a few joints or many joints and is predominantly seronegative, which means people generally do not have the blood markers often associated with other forms of inflammatory arthritis.

The condition can also be difficult to diagnose. Healthcare providers must consider other possible causes of joint symptoms, including cancer that has spread to the bones, fractures, infections and other immune-related side effects of treatment.

Research suggests that ICI-IA involves distinct immune processes, including the expansion of certain CD8+ T cells, which are immune cells that help the body recognize and destroy threats, including cancer cells. The same types of immune responses that help checkpoint inhibitors fight cancer may also contribute to joint inflammation, which makes treatment decisions especially complex.

Balancing joint health and cancer treatment

Treating ICI-IA requires careful consideration. The goal is to manage joint symptoms and protect quality of life while helping patients continue cancer treatment when appropriate. Achieving complete remission of arthritis is not always the primary treatment goal.

Treatment can include glucocorticoids, as well as conventional and biologic disease-modifying antirheumatic drugs. However, the choice of treatment must take into account its potential effects on cancer outcomes. The review article recommends using the lowest effective dose of immunosuppressive treatment for the shortest possible time.

“Managing this type of arthritis is not simply about treating joint inflammation,” says Dr. Jamal. “We need to consider the person’s cancer treatment and overall health, and make decisions together with the patient, their oncologist and rheumatologist.”

A diagnosis of ICI-IA does not automatically mean immunotherapy must stop permanently. Depending on the severity of symptoms and the person’s cancer treatment needs, the care team may consider continuing, pausing or restarting treatment.

More research is needed

Important questions remain about who is most likely to develop ICI-IA, how to identify it reliably and which treatments offer the best balance between controlling arthritis and preserving the benefits of cancer treatment.

For people who receive cancer immunotherapy, new or worsening joint pain, swelling or stiffness is worth discussing with their healthcare team. Patients should not stop or change cancer treatment without first speaking with their care team.

Read the review article here.

Research Changes Real Lives

Behind every study is a person. Meet some Canadians whose lives are moving forward thanks to arthritis research.

Related News & Resources

Stay Informed with Arthritis Research Canada

Name

Stay Connected

Get the latest arthritis research news and events delivered to your inbox.

Name